Pfizer earn­ings top es­ti­mates on higher sales

The Myanmar Times - - International Business -

Pfizer re­ported bet­ter-than-ex­pected sec­ond-quar­ter earn­ings due to solid sales of sev­eral pharma prod­ucts that off­set the hit from the strong dol­lar.

Net in­come fell 23.1 per­cent from the year-ago pe­riod to US$2 bil­lion. Sales rose 10.9pc to $13.1 bil­lion. How­ever, costs in sev­eral cat­e­gories rose. Lead­ing drugs that helped boost per­for­mance in­cluded the breast can­cer drug Ibrance, the blood clot drug Eliquis and Lyrica, which treats pain.

Newspapers in English

Newspapers from Myanmar

© PressReader. All rights reserved.